VCYT VERACYTE, INC.

CIK 0001384101 20 ready 8-Ks latest May 5, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 20

Latest filing May 5, 2026, 7:59 PM ET

Top materiality 0.85

Event mix earnings ×11 · leadership ×3 · other_material ×2

Sentiment 11 pos · 0 neg · 9 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for VCYT

Highest-materiality recent filing

Veracyte Q4 revenue $118.6M (+21%), net income $5.1M vs. loss a year ago

February 24, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Q4 total revenue $118.6M (+21%), testing revenue $112.2M (+24%), testing volume +25% to 39,107 tests.
Q4 net income $5.1M vs. net loss in Q4 2023; adjusted EBITDA $26.1M (22.0% margin), up 76%.

Read filing →

May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Veracyte Q1 2026 revenue $139.1M (+21% YoY); GAAP net income $28.7M, adj. EBITDA $42.8M

Total revenue $139.1M (+21% YoY); testing revenue $135.1M (+26% YoY).
March 16, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026

Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.
February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Veracyte Q4 revenue $140.6M (+19% YoY); GAAP net income $41.1M, generates $52.6M operating cash

Q4 total revenue $140.6M (+19% YoY); testing revenue $135.8M (+21%); total volume 48,019 tests (+16%).
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M

FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.
November 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%

Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.
August 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Veracyte Q2 revenue $130.2M (+14% YoY); raises testing revenue guidance

Total revenue of $130.2M (+14% YoY); testing revenue of $122.3M (+14%).
May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%

Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).
February 24, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Veracyte Q4 revenue $118.6M (+21%), net income $5.1M vs. loss a year ago

Q4 total revenue $118.6M (+21%), testing revenue $112.2M (+24%), testing volume +25% to 39,107 tests.
November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M

Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).
August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes

Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).
June 13, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Veracyte stockholders approve 5M share increase under 2023 equity plan

Annual meeting held June 12, 2024; all four proposals passed.
May 7, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%

Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.
April 17, 2024, 7:59 PM ET M&A materiality 0.70 neutral item 9.01

Veracyte completes C2i acquisition for up to $95M stock; C2i had $36M loss, $78.6M debt

Acquisition closed Feb 5, 2024; total consideration up to $95M in Veracyte common stock.
February 22, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Veracyte Q4 revenue $98.2M (+22% YoY); full-year $361.1M (+22%)

Q4 2023 revenue $98.2M, up 22% YoY; testing revenue $90.4M (+29%).
February 6, 2024, 6:59 PM ET M&A materiality 0.70 neutral item 2.01 item 9.01 item 3.02 ◈ M&A Transactions

Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M

Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.

Executive changes

Appointed

Tom Miller

Director

VCYT · VERACYTE, INC.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.

Appointed

Brent Shafer

Director

VCYT · VERACYTE, INC.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.

Departed

John L. Bishop

Director

VCYT · VERACYTE, INC.

Filed: February 13, 2024, 6:59 PM ET

On February 7, 2024, John L. Bishop, a member of the Board of Directors (the “Board”) of Veracyte, Inc. (the “Company”), informed the Chair of the Board that he will retire at the end of his current term as director and not stand for reelection at the Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”).

Earnings & guidance

2026-Q1 EPS reported $0.35 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event earnings

11 positive 0 negative 9 neutral

source · VCYT on sec.gov